Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company’s common stock with an exercise price of $6.79, the closing trading price of the Company’s common stock on the Nasdaq Global Market on...
Coterra Energy Inc. (CTRA - $28.06) and Devon Energy Corp. (DVN - $39.94)News Reports Companies Near Potential Tie-Up to Create $60 Billion US Shale Group. According to the Financial Times, CTRA and DVN are in advanced talks about a combination that would create one of the largest oil and natural g
Oak Valley Bancorp and Oak Valley Community Bank Chief Executive Officer to Retire OAKDALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Oak Valley Bancorp (NASDAQ: OVLY), the bank holding company for Oak Valley Community Bank and Eastern Sierra Community Bank, announced that Christopher M. Courtney has notified the Boards of his intention to retire as Chief Executive Officer of both entities on June 30, 2026. Courtney joined Oak Valley Community Bank in 1996 and served in several executive leadership roles, including EVP Chief Operating Officer and EVP Chief Credit Officer. He became Presi...
SkyWater Technology Inc. (SKYT - $31.32) and IonQ, Inc. (IONQ - $47.25)Announces $1.8 Billion Cash & Stock Acquisition; Offer Value $35.00/share ($15 Cash + $20 Stock, Subject to Collar); Expected Close 2/3Q' 2026. IONQ announced on January 26, 2026, that it has entered into a definitive agreem
Oak Valley Bancorp Reports 4th Quarter Results and Announces Cash Dividend OAKDALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Oak Valley Bancorp (NASDAQ: OVLY) (the “Company”), the bank holding company for Oak Valley Community Bank and their Eastern Sierra Community Bank division, recently reported unaudited consolidated financial results. For the three months ended December 31, 2025, consolidated net income was $6,335,000 or $0.76 per diluted share (EPS), as compared to $6,693,000, or $0.81 EPS, for the prior quarter and 6,008,000, or $0.73 EPS for the same period a year ago. Consolidate...
Amicus Therapeutics Inc. (NASDAQ: FOLD - $14.35) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - $56.77)Filed Preliminary Proxy; Highlights From Background of Merger Agreement. FOLD filed its preliminary proxy with details regarding the background of BMRN's acquisition of FOLD, beginning with FOLD
Oak Valley Community Bank Welcomes Carlos Chavez as Vice President, Branch Manager of Stockton Branch OAKDALE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), is pleased to welcome Carlos Chavez as Vice President, Branch Manager. Chavez will oversee the bank’s Stockton Branch at 2935 West March Lane, where he will be responsible for guiding branch operations, strengthening client relationships, and driving growth through a continued commitment to service excellence. His role will also include supporting t...
Oak Valley Community Bank Announces Leadership Team Promotions OAKDALE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oak Valley Bancorp (NASDAQ: OVLY), the bank holding company for Oak Valley Community Bank and its Eastern Sierra Community Bank division, today announced the promotions of Bill Nunes to Executive Vice President, Chief Marketing Officer, and Jose Sabala to Senior Vice President, Community Reinvestment Act (CRA) Officer. Bill Nunes — Executive Vice President, Chief Marketing OfficerNunes joined the Bank in 2005 and most recently served as Senior Vice President, Marketing Manage...
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., ...
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company’s common stock with an exercise price of $6.76, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.